The Endocrine System

Fundamental Electrolyte Imbalances in Endocrine Regulation

• Sodium Regulation and Imbalances:

  • Hyponatremia ($< 135$):

    • Clinical Manifestations: Poor skin turgor, dry mucous membranes, headache, decreased salivation, decreased blood pressure, increased heart rate (tachycardia), nausea, abdominal cramping, and neurological changes.

    • Laboratory Profile: Decreased serum sodium ($< 135$) is accompanied by decreased serum osmolality and decreased blood urea nitrogen (BUN).

    • Clinical Pearl: "Liquid body = low labs" (fluid overload states dilute lab values).

  • Hypernatremia ($> 145$):

    • Clinical Manifestations: Intense thirst, elevated temperature, dry tongue, sticky mucous membranes, lethargy, irritability, seizures, low heart rate, high blood pressure (elevated BP), and high respiratory rate (RR).

    • Laboratory Profile: Increased serum sodium ($> 145$) is accompanied by increased serum osmolality and high BUN.

• Calcium Regulation and Imbalances:

  • Hypercalcemia ($> 10.2$):

    • Clinical Manifestations: Polyuria, polydipsia (thirst), profound muscle weakness, intractable nausea, abdominal cramps, severe constipation, diarrhea, peptic ulcer disease, bone pain, electrocardiogram (ECG) changes, cardiac dysrhythmias, elevated heart rate (high HR), and low blood pressure (low BP).

  • Hypocalcemia ($< 8.6$, noted in clinical review as thresholds deviating below normal reference ranges down from $8.6$):

    • Clinical Manifestations: Neuromuscular excitability and tetany, circumoral numbness, paresthesias, hyperactive deep tendon reflexes (DTRs), positive Trousseau sign (carpopedal spasm induced by ischemia via blood pressure cuff), positive Chvostek sign (facial nerve twitching elicited by tapping over the facial nerve anterior to the ear), seizures, respiratory symptoms including dyspnea and laryngospasm, abnormal blood clotting, marked anxiety, low blood pressure (low BP), and abnormal heart rate.

Foundations of the Endocrine System

• Systemic Overview and Physiological Scope:

  • The endocrine system orchestrates vital cellular interactions, basal and active metabolism, somatic growth, reproductive processes, systemic aging, and adaptation/response to adverse conditions or physiological stress.

  • Regulatory Mechanism: Operates predominantly via negative feedback mechanisms to maintain homeostatic set points.

• Biochemical Classification of Hormones:

  • Amines and Amino Acids: Simple chemical modifications of amino acid residues.

  • Peptides, Polypeptides, Proteins, and Glycoproteins: Hydrophilic macromolecules that bind directly to surface receptors on target cell membranes.

  • Steroids: Lipophilic compounds derived from cholesterol that permeate cell membranes to act on intracellular receptors located in the cytoplasm or nucleus.

  • Fatty Acid Derivatives: Eicosanoids and related signaling molecules.

The Hypothalamus and Hypothalamic-Pituitary Axis

• Functional Role:

  • Serves as the central integrator linking the nervous system directly to the endocrine system.

  • Directs and controls the release of anterior pituitary hormones through vascular hypophyseal portal systems.

• Major Hypothalamic Releasing and Inhibiting Hormones:

  • Corticotropin-Releasing Hormone (CRH): Stimulates the synthesis and release of adrenocorticotropic hormone (ACTH) by the anterior pituitary.

  • Thyrotropin-Releasing Hormone (TRH): Directs the anterior pituitary to secrete thyroid-stimulating hormone (TSH).

  • Growth Hormone-Releasing Hormone (GHRH): Stimulates the secretion of growth hormone (GH) / somatotropin.

Pituitary Gland Structure, Secretions, and Physiological Roles

• Structural Overview:

  • Designated historically as the "Master Gland," nestled in the sella turcica of the sphenoid bone.

  • Divided into two functionally and embryologically distinct lobes: the Anterior Pituitary (Adenohypophysis) and the Posterior Pituitary (Neurohypophysis).

• Essential Bodily Functions Mediated by Pituitary Secretions:

  • Somatic growth and tissue maintenance.

  • Metabolic rate and energy turnover regulation.

  • Reproductive competency, gametogenesis, and gonadal control.

  • Adaptive response to acute trauma and psychological or systemic stress.

  • Lactation and postpartum mammary glandular activity.

  • Systemic water balance and sodium equilibrium.

  • Uterine contractility during labor and childbirth.

• Hormones of the Anterior Pituitary (Adenohypophysis):

  • Adrenocorticotropic Hormone (ACTH): Responds directly to physiological stress by stimulating the adrenal cortex to produce cortisol (the primary systemic "stress hormone"). Controls carbohydrate and protein metabolism, assists in blood pressure maintenance, regulates blood glucose levels, and dampens inflammatory reactions.

  • Follicle-Stimulating Hormone (FSH): Regulates gametogenesis; stimulates sperm maturation in males and estrogen production along with follicular maturation in females.

  • Luteinizing Hormone (LH): Triggers ovulation in females and stimulates testosterone biosynthesis in males, controlling the endocrine function of the gonads (ovaries and testes).

  • Growth Hormone (GH) / Somatotropin: Stimulates tissue, bone, and visceral growth; exerts significant systemic metabolic influences on protein synthesis, lipolysis, and glucose utilization.

  • Prolactin (PRL): Targets mammary alveolar tissue to stimulate and sustain postpartum breast milk production.

  • Thyroid-Stimulating Hormone (TSH): Stimulates the thyroid gland to produce and secrete thyroid hormones ($T_3$ and $T_4$) that govern baseline metabolic rate, whole-body energy kinetics, and central and peripheral nervous system dynamics.

• Hormones of the Posterior Pituitary (Neurohypophysis):

  • Antidiuretic Hormone (ADH / Vasopressin): Synthesized in hypothalamic nuclei, transported axonally, and released from the posterior lobe. Regulates systemic fluid retention and plasma sodium levels via water reabsorption in renal collecting tubules; acts as a potent systemic vasoconstrictor.

  • Oxytocin: Synthesized in the hypothalamus, stored in and released from the posterior pituitary. Stimulates uterine contractions during labor and induces milk ejection ("let-down reflex") during lactation.

• Summary of Pituitary Hyper- and Hypofunction Disorders:

  • Anterior Pituitary:

    • Hypersecretory States: Cushing's disease/syndrome (secondary to ACTH elevation), Gigantism (excess GH pre-epiphyseal closure), Acromegaly (excess GH post-epiphyseal closure).

    • Hyposecretory States: Pituitary Dwarfism (deficient GH), Panhypopituitarism (global anterior trophic hormone failure).

  • Posterior Pituitary:

    • Hypersecretory State: Syndrome of Inappropriate Antidiuretic Hormone (SIADH).

    • Hyposecretory State: Diabetes Insipidus (DI).

  • Pathology and Surgical Interventions: Most neoplasms involving the pituitary gland are benign adenomas. Definitive surgical resection is achieved via hypophysectomy (typically transsphenoidal).

Anterior Pituitary Disorders: Somatotropin Aberrations

• Gigantism:

  • Pathophysiology: Characterized by hypersecretion of somatotropin (growth hormone, GH) occurring in pediatric populations prior to the closure of epiphyseal growth plates.

  • Clinical Presentation: Results in accelerated, proportional tissue, skeletal, and longitudinal growth throughout all extremities and visceral structures.

• Acromegaly:

  • Pathophysiology: Hypersecretion of somatotropin occurring in adulthood after the fusion of epiphyseal growth plates.

  • Clinical Presentation: Disproportional growth of peripheral tissues, bones, and cartilage; vertical stature (height) is less affected.

  • Specific Manifestations: Enlargement of facial bones (frontal bossing, mandibular prognathism), broad hands, enlarged feet, tongue enlargement, coarsening of facial features, deep voice, and soft tissue hypertrophy.

• Dwarfism:

  • Pathophysiology: Caused by subnormal secretion (hyposecretion) of GH during childhood development. Usually associated with panhyposecretion involving multiple anterior pituitary hormones.

  • Clinical Manifestations:

    • Markedly delayed, slow-growing skeletal system and stunted vertical height.

    • Development of childhood obesity.

    • High-pitched voice (due to hypotestosterone / deficient gonadotropic stimulation).

    • Elevated serum lipid/fat concentrations (secondary to impaired adrenal axis and altered cortisol dynamics).

Thyroid Gland Physiology and Hormonal Regulation

• Anatomical Structure and Secretory Profile:

  • Located anterior to the upper trachea; highly vascularized endocrine organ producing three major hormones: Triiodothyronine ($T_3$), Thyroxine ($T_4$), and Calcitonin.

  • Dietary iodine is indispensable for the biochemical synthesis of thyroid hormones.

• Hormone Actions and Kinetics:

  • Triiodothyronine ($T_3$): Possesses significantly greater biological potency and acts much more rapidly than $T_4$.

  • Thyroxine ($T_4$): Secreted in greater abundance; converted peripherally to the biologically active $T_3$.

  • Metabolic Control: Directly governs baseline cellular metabolic activity, oxygen consumption, and energy turnover across all bodily tissues.

  • Control Axis: The synthesis and peripheral secretion of thyroid hormones are strictly regulated by TSH released from the anterior pituitary, which itself responds to hypothalamic TRH via negative feedback inhibition.

Calcitonin Mechanism and Calcium Homeostasis

• Source and Secretory Trigger:

  • Secreted by the parafollicular cells of the thyroid gland (acting in coordination/opposition to the parathyroid glands).

  • Release is directly stimulated by elevated serum/plasma calcium concentrations.

• Physiological Mechanisms of Calcitonin Action:

  • Skeletal Target: Stimulates osteoblastic activity while directly inhibiting osteoclasts, sequestering and depositing ionized calcium into the skeletal matrix.

  • Renal Target: Inhibits tubular reabsorption of calcium and inorganic phosphate, promoting urinary excretion.

  • Intestinal Target: Limits systemic enteral absorption of calcium.

  • Overall Effect: Rapidly lowers circulating ionized calcium levels in the intravascular pool.

• Feedback Dynamics:

  • Elevated serum calcium triggers calcitonin secretion.

  • Depressed serum calcium suppresses calcitonin secretion, permitting parathyroid hormone (PTH) to dominate.

Thyroid Diagnostic Evaluation and Laboratory Testing

• Diagnostic Modalities:

  • Serum TSH Assay: The primary, single best screening test to localize pathology along the hypothalamic-pituitary-thyroid axis (differentiates primary thyroid gland dysfunction from central pituitary or hypothalamic lesions).

  • Serum Free $T_4$ ($\text{FT}_4$) and Free $T_3$ ($\text{FT}_3$): Measured as the active, unbound fraction of circulating hormones; directly demonstrates functional gland output.

  • Thyroid Antibodies: High serum titers confirm autoimmune thyroid disease (e.g., anti-TPO, thyroglobulin antibodies in Hashimoto's thyroiditis; thyroid-stimulating immunoglobulins in Graves' disease).

  • Radioactive Iodine Uptake (RAIU): Measures the percentage of orally administered radioiodine localized by the gland to evaluate metabolic turnover.

  • Fine-Needle Aspiration (FNA) Biopsy: Standard cytological technique used to differentiate benign nodular goiters from thyroid malignancies.

  • Thyroid Scintiscan: Scans anatomical distribution of radionuclide to assess nodular function ("hot" vs. "cold" nodules).

• Interpretation of Thyroid Function Tests:

  • Primary Hypothyroidism (Thyroid Insufficiency, e.g., Hashimoto's Thyroiditis): High TSH ($\uparrow$), Low $\text{FT}_4$ ($\downarrow$), Low $\text{FT}_3$ ($\downarrow$).

  • Secondary Hypothyroidism (Pituitary or Hypothalamic Insufficiency): Low TSH ($\downarrow$), Low $\text{FT}_4$ ($\downarrow$), Low $\text{FT}_3$ ($\downarrow$).

  • Hyperthyroidism (Primary, e.g., Graves' Disease): Low TSH ($\downarrow$), High $\text{FT}_4$ ($\uparrow$), High $\text{FT}_3$ ($\uparrow$).

  • $T_3$ Thyrotoxicosis: Low TSH ($\downarrow$), Normal $\text{FT}_4$ ($\text{N}$), High $\text{FT}_3$ ($\uparrow$).

Hypothyroidism and Myxedema Crisis

• Classification and Etiology:

  • Primary Hypothyroidism: Intrinsic gland destruction due to autoimmune inflammation (Hashimoto's thyroiditis—affecting females 5 times more frequently than males), congenital dysgenesis, surgical ablation, antithyroid pharmacotherapy, or inadequate dietary iodine. Serum labs reveal high TSH, low $T_3$/$T_4$, and secondary hyponatremia due to blunted adrenal cortical responsiveness.

  • Secondary Hypothyroidism: Failure of pituitary TSH secretion (or hypothalamic TRH failure). Serum labs reveal subnormal/low TSH alongside low $T_3$/$T_4$.

  • Cretinism: Untreated congenital hypothyroidism presenting in pediatric populations; produces irreversible stunting of physical growth and cognitive development.

  • Goiter: Glandular enlargement triggered by chronic elevated TSH drive resulting from iodine deficiency, or intrinsic inflammatory infiltration.

• Clinical Presentation:

  • Systemic slowing of all metabolic parameters ("Low and Slow"):

    • Profound generalized fatigue, weakness, and somnolence.

    • Dry skin, brittle nails, coarse thinning hair, and loss of lateral eyebrows.

    • Facial puffiness and periorbital edema.

    • Subnormal core body temperature and cold intolerance.

    • Bradycardia, hypotension, and decreased cardiac output.

    • Unexplained weight gain despite anorexia or reduced caloric intake.

    • Chronic constipation and abdominal distention.

    • Peripheral paresthesias and numbness/tingling of the fingers.

    • Subdued, blunted emotional affect, slowed speech, impaired memory, and cognitive deterioration.

    • Heavy, irregular menstrual bleeding (menorrhagia).

    • Myalgias, arthralgias, and depressed deep tendon reflexes.

• Myxedema and Myxedema Coma (Hypothyroid Crisis):

  • Pathology: The most extreme, life-threatening progression of severe, decompensated hypothyroidism, often precipitated by systemic infection, exposure to cold, or sedative administration.

  • Mechanism: Severe hypometabolic state wherein mucopolysaccharides and abnormal glucose derivatives accumulate within subcutaneous and interstitial spaces, drawing fluid and causing universal non-pitting edema.

  • Clinical Findings:

    • Dull, puffy facial expression with marked periorbital edema.

    • Dry, coarse, sparse scalp hair with loss of the outer third of the eyebrows.

    • Pretibial non-pitting edema.

    • Severe core hypothermia, shallow/slow bradypnea, and severe bradycardia (pulse $< 60\,\text{beats per minute}$).

    • Significant hypotension and decreased vascular tone.

    • Slurred speech, severe hoarseness, absent or sluggish deep tendon reflexes.

    • Rapid neurological decline transitioning from lethargy and confusion to stupor, coma, and cardiovascular collapse.

• Medical Management of Hypothyroidism:

  • Pharmacotherapy: Lifelong daily hormone replacement with synthetic levothyroxine (Synthroid).

  • Administration Rules: Must be taken consistently in the morning on an empty stomach with a full glass of water, minimum $30\text{--}60\,\text{minutes}$ prior to caloric intake.

  • Drug-Drug Interactions:

    • Enteral absorption is significantly impaired by concurrent administration of antacids and iron supplements.

    • Psychotropic agents, including antianxiety and antipsychotic medications, alter systemic absorption and metabolism.

    • Potentiates the pharmacodynamic effects of oral anticoagulants (warfarin), requiring careful titration to prevent severe hemorrhage.

  • Dosing Sensitivity: Dosing is individualized; minor microgram changes exert profound alterations on metabolic rate.

  • Therapeutic Target: Restoration and maintenance of a clinical and biochemical euthyroid state.

Hyperthyroidism, Graves' Disease, and Thyroid Storm

• Epidemiology and Etiology:

  • Second most prevalent endocrine disorder; marked by excessive functional synthesis and peripheral release of thyroid hormones ($T_3$ and $T_4$).

  • Etiologies: Toxic multinodular goiter, thyroiditis, functioning thyroid carcinomas, pituitary adenomas secreting TSH, excessive exogenous thyroid replacement, and Graves' disease.

  • Graves' Disease: The single most common cause, seen primarily in women under the age of $40$. An autoimmune disorder characterized by circulating autoantibodies (thyroid-stimulating immunoglobulins) that bind persistently to TSH receptors, triggering uninhibited overproduction of $T_3$ and $T_4$.

• Clinical Presentation:

  • Systemic acceleration of metabolic rate ("Everything Speeds Up"):

    • Unintentional, rapid weight loss despite a voraciously increased appetite.

    • Elevated basal body temperature, profuse diaphoresis, and marked heat intolerance.

    • Cardiovascular hyperactivity: resting tachycardia, bounding peripheral pulses, palpitations, arterial hypertension, and atrial dysrhythmias.

    • Hyperactive gastrointestinal motility, frequent bowel movements, and diarrhea.

    • Neuromuscular agitation: fine tremors of the fingers and tongue, extreme nervousness, heightened irritability, mood lability, and intractable insomnia.

    • Dermatological/hair alterations: warm, moist, flushed skin, accelerated nail growth, and fine, soft, brittle hair.

    • Reproductive changes: oligomenorrhea or amenorrhea in females.

    • Exophthalmos (Proptosis): Bilateral bulging of the globes, retraction of upper eyelids, conjunctival injection/redness, and scleral exposure, caused by retro-orbital mucopolysaccharide deposition and lymphocytic infiltration.

• Thyroid Storm (Thyrotoxic Crisis):

  • Pathology: An acute, deadly hypermetabolic emergency resulting from an abrupt release of massive amounts of thyroid hormones into the circulation.

  • Red "FLAGS" Clinical Criteria:

    • F – Fever: Hyperpyrexia ranging between $104^\text{o}\text{F}$ and $106^\text{o}\text{F}$.

    • L – Low Blood Pressure: Hypotension progressing rapidly toward overt circulatory collapse and shock.

    • A – Arrhythmias and HR: Severe cardiac arrhythmias, extreme resting tachycardia with heart rate $> 140\,\text{beats per minute}$.

    • G – GI Distress: Intractable nausea, vomiting, abdominal pain, diarrhea, and jaundice.

    • S – Sweating: Profuse diaphoresis causing severe dehydration.

• Medical and Surgical Management:

  • Radioactive Iodine ($^{131}\text{I}$) Therapy: Oral therapeutic isotope concentrates within thyroid follicular cells, leading to targeted ablative destruction.

  • Thionamide Antithyroid Pharmacotherapy:

    • Propylthiouracil (PTU): Blocks thyroid hormone synthesis and prevents peripheral conversion of $T_4$ to $T_3$.

    • Methimazole: Inhibits thyroid hormone synthesis.

  • Adrenergic Blockade: Beta-adrenergic antagonists (e.g., propranolol) administered to immediately control cardiovascular adrenergic toxicity (tachycardia, hypertension, palpitations, tremor).

  • Surgical Intervention: Subtotal or total thyroidectomy.

  • Therapeutic Caveat: Clinical relapse is common; medical or surgical suppression carries a high probability of inducing permanent post-treatment hypothyroidism.

Surgical Management of Thyroid Pathology (Thyroidectomy)

• Indications: Treatment of choice for persistent thyroid malignancies or cases of toxic hyperthyroidism unresponsive or unsuitable for radioiodine/medical suppression.

• Operative Procedures: Subtotal thyroidectomy, total thyroidectomy, or comprehensive resections involving modified or radical neck dissections for metastatic lymphatic disease.

• Preoperative Care Goals:

  • Eliminate stress and systemic metabolic excitement to prevent the intraoperative induction of thyroid storm.

  • Provide targeted pre-op instruction regarding dietary support, surgical neck support techniques, and postoperative airway maintenance.

• Postoperative Monitoring and Nursing Care:

  • Airway Security: Priority clinical focus; ensure immediate access to emergency tracheostomy equipment at bedside. Observe for stridor or sudden respiratory distress.

  • Hemorrhage Assessment: Inspect surgical dressing and posterior aspect of the neck/shoulders for overt pooling; monitor for expanding cervical hematoma causing tracheal compression.

  • Positioning: Maintain patient in Semi-Fowler's position with neutral head alignment supported by pillows to avoid suture line tension.

  • Voice and Laryngeal Nerve Assessment: Periodically assess vocal quality to rule out recurrent laryngeal nerve damage; discourage unnecessary conversational talking to minimize edema.

  • Hypocalcemia Vigilance: Inadvertent trauma, devascularization, or excision of the parathyroid glands during surgery can induce acute hypocalcemia. Closely monitor for neuromuscular irritability, perioral paresthesias, positive Chvostek's sign, and positive Trousseau's sign.

Parathyroid Physiology and Disorders: Hypoparathyroidism and Hyperparathyroidism

• Anatomy and Physiological Function:

  • Four micro-glands embedded bilaterally along the posterior surface of the thyroid capsules.

  • Parathormone (PTH) Regulation: PTH serves as the primary hormonal regulator of calcium and phosphorus homeostasis:

    • Bone: Activates osteoclasts to resorb bone, releasing ionized calcium into the blood pool (chronic overproduction leads to pathological demineralization).

    • Kidney: Directly promotes renal tubular reabsorption of calcium while promoting tubular excretion of inorganic phosphorus (lowering plasma phosphate); stimulates renal conversion of vitamin D into its active form.

    • Intestine: Active vitamin D stimulates the gastrointestinal mucosal epithelium to absorb calcium from nutritional intake.

  • Feedback Axis: Regulated strictly via negative feedback—low ionized serum calcium triggers PTH secretion; elevated serum calcium halts PTH release.

• Hypoparathyroidism:

  • Etiology: Typically iatrogenic following thyroidectomy, parathyroidectomy, or extensive radical neck dissection.

  • Biochemical Hallmarks: Profound deficiency of PTH yielding hypocalcemia and reciprocal hyperphosphatemia.

  • Clinical Presentation:

    • Overt neuromuscular irritability and spontaneous tetany.

    • Positive Chvostek's sign (facial twitch on percussing the facial nerve).

    • Positive Trousseau's sign (carpopedal spasm elicited by ischemic cuff pressure).

    • Skeletal stiffness of hands, wrists, feet, and ankles.

    • Paresthesias and numbness of distal extremities and perioral region.

    • Life-threatening bronchospasm and laryngeal spasms causing acute stridor.

    • Neuropsychiatric disturbances: anxiety, emotional irritability, depression, and progressive delirium.

    • Cardiac ECG alterations: prolonged QT intervals and conduction defects.

  • Management Strategies:

    • Rapid restoration of serum calcium levels within normal limits via IV calcium gluconate for acute crises; long-term oral calcium salts and high-dose active Vitamin D metabolites.

    • Parenteral administration of parathormone injections.

    • Environmental control: maintenance of a calm environment free of loud noise, drafts, bright lights, and sudden mechanical movements to prevent triggering tetanic spasms.

    • Nutritional therapy: high-calcium, low-phosphorus dietary intake.

• Hyperparathyroidism:

  • Etiology: Unregulated autonomous overproduction of PTH, most commonly arising from a solitary benign parathyroid adenoma.

  • Biochemical Hallmarks: Hypercalcemia coupled with hypophosphatemia.

  • Clinical Presentation:

    • Nephrolithiasis: recurrent calcium phosphate/oxalate kidney stones.

    • Arterial hypertension, ventricular arrhythmias, and shortened QT intervals.

    • Extreme emotional lability, mood swings, and psychosis.

    • Skeletal fragility: pathological fractures, marked osteopenia, and generalized bone pain.

    • Profound generalized fatigue and peripheral muscle weakness.

  • Management Strategies:

    • Calcimimetic pharmacotherapy: Cinacalcet (sensitizes parathyroid calcium-sensing receptors, suppressing PTH secretion).

    • Bisphosphonate administration to halt osteoclastic bone resorption and protect skeletal integrity.

    • Avoidance of thiazide diuretics and lithium carbonate, as both agents elevate serum calcium.

    • Surgical excision of the hyperfunctioning adenoma/gland for moderate to severe disease.

    • Continuous serial biochemical monitoring of ionized serum calcium.

Adrenal Gland Anatomy, Secretions, and Hormonal Classifications

• Anatomical Overview: Bilateral, pyramid-shaped endocrine structures situated retroperitoneally atop the superior pole of each kidney, divided into two physiologically distinct glandular zones: the Adrenal Medulla and the Adrenal Cortex.

• Adrenal Medulla:

  • Acts functionally as a specialized neuroendocrine extension of the sympathetic branch of the autonomic nervous system.

  • Synthesizes and secretes catecholamines directly into systemic circulation: Epinephrine ($\approx 85\%$) and Norepinephrine ($\approx 15\%$).

• Adrenal Cortex (The "Three S's"):

  • Sugar (Glucocorticoids): Primarily Cortisol and Cortisone. Regulate carbohydrate, lipid, and protein catabolism; stimulate hepatic gluconeogenesis; regulate systemic blood pressure; and suppress cellular inflammation.

  • Salt (Mineralocorticoids): Primarily Aldosterone. Regulates distal renal tubular ion exchange, stimulating active sodium retention and water reabsorption while driving potassium excretion into the urine.

  • Sex (Androgens): Adrenal sex steroids. Contribute to secondary sexual characteristics, pubertal development, and nitrogen retention.

Adrenocortical Insufficiency (Addison's Disease) and Adrenal Crisis

• Pathology and Etiology:

  • Primary hypofunction of the adrenal cortex causing severe deficiency of cortisol, aldosterone, and adrenal androgens ("Add more").

  • Risk Factors / Causes: Autoimmune destruction of the adrenal cortex, bilateral adrenal hemorrhage, systemic tuberculosis (TB) infection, metastatic invasion, or traumatic injury/pituitary suppression affecting the brain.

• Clinical Presentation:

  • Profound, progressive muscle weakness, generalized fatigue, and anorexia with gastrointestinal disturbances.

  • Characteristic dark, bronze hyperpigmentation of the skin (especially skin creases, pressure points, and oral mucous membranes), caused by elevated compensatory pro-opiomelanocortin and ACTH output.

  • Severe postural hypotension and orthostasis due to aldosterone deficiency.

  • Electrolyte and metabolic imbalances: Hypoglycemia, Hyponatremia (depleted sodium), Hyperkalemia (retention of potassium).

  • Psychiatric alterations: emotional apathy, profound affective lability, and confusion.

  • Changes in secondary sexual hair distribution and weight loss.

• Addisonian Crisis (Acute Adrenal Crisis):

  • Pathology: A life-threatening state of complete circulatory collapse and vascular instability, precipitated by physiological stress (e.g., trauma, surgery, infection) or abrupt cessation of exogenous corticosteroid therapy.

  • Clinical Hallmarks: Profound prostrating fatigue, severe dehydration, irreversible vascular collapse with refractory hypotension, acute renal shutdown, profound hyponatremia, and critical hyperkalemia.

• Diagnostic Evaluation:

  • Serum basal adrenocortical hormones (cortisol, aldosterone).

  • Elevated plasma ACTH levels in primary adrenal failure.

  • ACTH Stimulation Test: failure of the adrenal cortex to elevate serum cortisol following exogenous synthetic ACTH confirms primary adrenal insufficiency.

  • Serum electrolyte panel demonstrating low sodium and elevated potassium.

• Medical Management:

  • Immediate fluid and electrolyte resuscitation: rapid infusion of $0.9\%$ Normal Saline (NS) or $5\%$ Dextrose in $0.9\%$ Saline ($\text{D}_5\text{W}\;0.9\%\;\text{NS}$) to reverse hypovolemia, hypoglycemia, and hyponatremia.

  • Lifelong systemic glucocorticoid replacement (e.g., hydrocortisone, divided into circadian doses), coupled with mineralocorticoid therapy (fludrocortisone) when indicated.

  • Patient education regarding strict stress dosing protocols, aggressive hydration maintenance, and adherence to a diet moderate in sodium and strictly low in potassium.

Hypercortisolism: Cushing's Syndrome

• Etiology:

  • Hyperfunctioning adrenal cortex resulting in excessive circulating glucocorticoids (excess cortisol; "cushion, too much").

  • Underlying Causes: Hypersecretion of ACTH from a benign pituitary adenoma (Cushing's disease), autonomous primary benign or malignant adrenal cortical tumors, ectopic ACTH production (e.g., small cell lung carcinomas), or prolonged administration of pharmacological doses of exogenous corticosteroids.

• Clinical Presentation:

  • Metabolic Alterations: Marked hyperglycemia, glucose intolerance, dynamic steroid-induced diabetes, and profound central-type obesity.

  • Somatic Adipose Distribution: "Buffalo hump" (cervicodorsal fat pad hypertrophy), round "moon-face," enlarged supraclavicular fat pads, and heavy central trunk with remarkably thin extremities secondary to muscle wasting.

  • Dermatological Deterioration: Fragile, paper-thin, transparent skin; widespread ecchymoses; prominent purple/violaceous striae across the abdomen, thighs, and breasts; severe acne; and delayed cutaneous wound healing.

  • Musculoskeletal Integrity: Severe osteoporosis, pathological compression fractures of the spine, osteopenia, marked muscle weakness, and profound lassitude.

  • Cardiovascular and Renal Fluid Dynamics: Secondary hypertension and fluid retention with peripheral edema, mediated by hypernatremia and hypokalemia.

  • Immunological Impact: Marked suppression of the immune response with high susceptibility to opportunistic infections.

  • Neuropsychiatric and Endocrine Effects: CNS irritability, emotional instability, personality changes, sleep disturbances, peptic acid hypersecretion (GI distress), virilization in females (hirsutism, clitoromegaly, amenorrhea), and gynecomastia and loss of libido in males.

• Diagnostic Evaluation:

  • Dexamethasone Suppression Test: Overnight low-dose dexamethasone fails to suppress morning plasma cortisol in hypercortisolemic patients.

  • 24-Hour Urinary Free Cortisol Collection: Demonstrates elevated excretion of unbound cortisol.

  • Serum electrolyte profile demonstrating persistent hypernatremia, hypokalemia, and metabolic alkalosis.

• Medical and Surgical Management:

  • Surgical excision of the offending neoplasm: transsphenoidal hypophysectomy for pituitary lesions; unilateral or bilateral adrenalectomy for primary adrenal adenomas/carcinomas.

  • Targeted chemotherapy for malignant or ectopic lesions.

  • Pharmacological inhibition of adrenal steroidogenesis: Metyrapone (blocks cortisol biosynthesis).

  • Nursing and supportive protocols: continuous blood glucose monitoring, fracture/fall risk precautions, low-fat/controlled-calorie nutrition, aggressive infection prevention, and psychosocial coping support.

Adrenal Medullary and Cortical Hyperfunction: Pheochromocytoma and Primary Aldosteronism

• Primary Aldosteronism (Conn's Syndrome):

  • Pathology: Autonomous hypersecretion of aldosterone arising from a benign aldosterone-secreting tumor of the adrenal cortex.

  • Physiological Cascades: Excess aldosterone drives exaggerated renal distal tubule sodium reabsorption and reciprocal excretion of potassium and hydrogen ions. Subsequent plasma expansion downregulates and suppresses circulating renin production.

  • Clinical Presentation: Severe arterial hypertension, hypervolemia with expansion of the extracellular fluid (ECF) volume, profound hypokalemia (causing muscle weakness, cramps, and paresthesias), hypernatremia, severe vascular headaches, and polyuria (increased urine output).

  • Treatment: Unilateral laparoscopic adrenalectomy; pre- and post-operative dietary management centered on a strictly high-potassium and low-sodium diet, augmented by aldosterone-antagonist diuretics (spironolactone).

• Pheochromocytoma:

  • Pathology: A functioning neuroendocrine chromaffin cell tumor of the adrenal medulla that continuously or paroxysmally hypersecretes excessive quantities of adrenaline (epinephrine) and noradrenaline (norepinephrine).

Posterior Pituitary Disorders: Diabetes Insipidus (DI) and SIADH

• Physiological Actions of Antidiuretic Hormone (ADH / Vasopressin):

  • Synthesized in the hypothalamus, released into the bloodstream by the posterior pituitary.

  • Regulates whole-body fluid balance, water conservation, and intravascular sodium concentrations.

  • Acts on the renal collecting ducts to promote free water reabsorption back into the plasma pool, preventing excessive diuresis.

  • Stimulates systemic vascular smooth muscle vasoconstriction, increasing peripheral vascular resistance and elevating systemic arterial blood pressure.

• Diabetes Insipidus (DI):

  • Etiology: Arises secondary to central craniotomy, head trauma, primary tumors, surgical ablation, or nephrogenic failure wherein renal tubules fail to respond to circulating ADH.

  • Pathophysiology: Complete deficiency or absent cellular effect of ADH, permitting massive volumes of free, unabsorbed water to be eliminated through the urinary tract.

  • Clinical Manifestations:

    • Profound, unremitting polydipsia with high fluid consumption ($2\text{--}20\,\text{L/day}$).

    • Excretion of enormous volumes of dilute urine (polyuria).

    • Neurological compromise secondary to rapid cellular dehydration.

    • Cardiac arrhythmias triggered by hypernatremia and accompanying hypokalemia.

    • Severe systemic dehydration, sunken fontanelles/eyes, and profound arterial hypotension.

  • Diagnostic Criteria:

    • Urinalysis revealing dilute urine with Urine Specific Gravity $< 1.005$.

    • Urine osmolality markedly reduced ($< 300\,\text{mOsm/kg}$).

    • Elevated serum sodium ($> 145\,\text{mEq/L}$, hypernatremia) and elevated serum osmolality ($> 295\,\text{mOsm/kg}$).

    • Subnormal or undetectable plasma ADH levels.

    • Water Deprivation Test: Fluids are withheld for $8\text{--}12\,\text{hours}$ or until $3\text{--}5\%$ of body weight is lost; ongoing inability of the kidneys to concentrate urine or increase specific gravity confirms the diagnosis of Diabetes Insipidus.

  • Treatment and Clinical Management:

    • Maintenance of vascular hydration status via hypotonic or isotonic intravenous infusions (e.g., $5\%$ Dextrose in Water, $\text{D}_5\text{W}$).

    • Identification and eradication of underlying intracranial or systemic causes.

    • Hormone replacement: Desmopressin (DDAVP) administered orally, parenterally, or intranasally; aqueous vasopressin IV for acute emergencies.

• Syndrome of Inappropriate Antidiuretic Hormone (SIADH):

  • Etiology: Arises from ectopic paraneoplastic production (e.g., small-cell bronchogenic carcinoma), neurosurgical operations, severe traumatic brain injuries, CNS infections, and specific pharmacotherapies.

  • Pathophysiology: Continuous, unregulated hypersecretion of ADH independent of plasma osmolality, producing pathological intravascular free water retention and severe dilutional states.

  • Clinical Manifestations:

    • Dilutional hyponatremia ($< 135\,\text{mEq/L}$, dropping below critical levels).

    • Hypervolemia and rapid weight gain without peripheral dependent edema.

    • Marked oliguria with dark, concentrated, low urine output.

    • Severe neurological decline: cerebral edema causing lethargy, progressive confusion, headache, blunted reflexes, seizures, coma, and brain herniation.

    • Generalized muscle cramping and profound weakness secondary to depleted intracellular and extracellular sodium.

  • Diagnostic Criteria: High urine osmolality, elevated urine sodium concentration ($> 20\,\text{mEq/L}$), accompanied by depressed serum osmolality and hyponatremia.

  • Treatment and Clinical Management:

    • Elimination of the primary causative factors.

    • Strict fluid restriction protocols (often $500\text{--}1000\,\text{mL/day}$).

    • Administration of loop diuretics (furosemide) if serum sodium is adequate.

    • Cautious infusion of hypertonic ($3\%$) saline for severe neurological emergencies, with strict control to avoid osmotic demyelination syndrome.

    • Serial neurological assessments, strict intake and output (I&O) recording, daily weight measurements, and continuous electrolyte monitoring.

Comprehensive Diagnostic and Clinical Comparison of Endocrine Disorders

• Thyroid Axis Comparison:

  • Hypothyroidism:

    • Physiological State: "Low and Slow."

    • Clinical Findings: Fatigue, depressed vital signs, weight gain, slowed speech, subnormal fasting blood sugar, cognitive slowing.

    • Laboratory Diagnostic Findings: High TSH, low $T_3$, low $T_4$.

    • Major Life-Threatening Complication: Myxedema Coma.

    • Medical Management: Daily morning administration of synthetic levothyroxine (Synthroid) on an empty stomach.

  • Hyperthyroidism:

    • Physiological State: Metabolic acceleration ("Everything Speeds Up").

    • Clinical Findings: Marked weight loss, increased appetite, elevated vital signs (tachycardia, HTN), hyperdefecation/diarrhea, extreme anxiety, profuse sweating, exophthalmos.

    • Laboratory Diagnostic Findings: Low TSH, elevated $T_3$, elevated $T_4$.

    • Major Life-Threatening Complication: Thyroid Storm (Thyrotoxic Crisis).

    • Medical/Surgical Management: Subtotal thyroidectomy, radioactive iodine ($^{131}\text{I}$), thionamides (PTU, methimazole), beta-adrenergic blockade.

• Parathyroid Calcium Axis Comparison:

  • Hypoparathyroidism:

    • Serum Electrolyte Profile: Low Calcium (Hypocalcemia), High Phosphorus (Hyperphosphatemia).

    • Clinical Features: Neuromuscular excitability, tetany, positive Chvostek's and Trousseau's signs, distal paresthesias, laryngospasm, bronchospasm, anxiety, prolonged QT intervals.

    • Management: Calcium replacement (IV calcium gluconate, oral calcium salts), active Vitamin D analogs, PTH injections, high-calcium low-phosphorus diet.

  • Hyperparathyroidism:

    • Serum Electrolyte Profile: High Calcium (Hypercalcemia), Low Phosphorus (Hypophosphatemia).

    • Clinical Features: Nephrolithiasis (kidney stones), arterial hypertension, shortened QT interval, emotional lability, generalized bone pain, pathological skeletal fractures, profound muscular fatigue.

    • Management: Parathyroidectomy, calcimimetics (Cinacalcet), bisphosphonates, avoidance of thiazide diuretics and lithium.

• Adrenal Cortical Axis Comparison:

  • Addison's Disease (Adrenocortical Hypofunction):

    • Hormone Output: Deficient Cortisol, deficient Aldosterone, deficient Androgens ("Add more").

    • Laboratory Diagnostics: Hypoglycemia, Hyponatremia ($\downarrow\;\text{Na}$), Hyperkalemia ($\uparrow\;\text{K}$), elevated plasma ACTH.

    • Clinical Features: Severe muscular asthenia, generalized fatigue, diffuse bronze hyperpigmentation, orthostatic hypotension, progressive confusion.

    • Critical Complication: Addisonian Crisis (vascular collapse, shock, renal shutdown).

    • Therapeutic Protocol: Intravenous isotonic saline and dextrose ($\text{D}_5\text{W}\;0.9\%\;\text{NS}$), lifelong glucocorticoid (hydrocortisone) and mineralocorticoid replacement, moderate sodium and low potassium intake.

  • Cushing's Syndrome (Adrenocortical Hyperfunction):

    • Hormone Output: Excessive Cortisol ("Cushion, too much").

    • Laboratory Diagnostics: Hyperglycemia, Hypernatremia ($\uparrow\;\text{Na}$), Hypokalemia ($\downarrow\;\text{K}$), failure to suppress on Dexamethasone Suppression Test.

    • Clinical Features: Truncal obesity, dorsal cervical "buffalo hump," "moon-face," wide purple abdominal striae, thin fragile skin, severe osteoporosis, ecchymosis, hypertension, heightened infection risk.

    • Therapeutic Protocol: Surgical resection of pituitary/adrenal neoplasms, chemotherapy, adrenal enzyme inhibitors (Metyrapone), fall precautions, tight glycemic control.

• Antidiuretic Hormone (ADH) Dynamic Axis Comparison:

  • Diabetes Insipidus (DI) (Posterior Hypofunction):

    • Hormonal Level: Deficient ADH.

    • Serum/Urine Laboratory Balance: Hypernatremia ($\uparrow\;\text{Na}$), elevated serum osmolality ($> 295\,\text{mOsm/kg}$), low urine specific gravity ($< 1.005$), low urine osmolality ($< 300\,\text{mOsm/kg}$).

    • Clinical Features: Extreme polyuria ($2\text{--}20\,\text{L/day}$), polydipsia, severe dehydration, arterial hypotension, neurological depression, cardiac arrhythmias.

    • Diagnostic Benchmark: Inability to concentrate urine during Water Deprivation Test.

    • Therapy: Fluid rehydration ($\text{D}_5\text{W}$), replacement of ADH with Desmopressin (DDAVP) or vasopressin.

  • SIADH (Posterior Hyperfunction):

    • Hormonal Level: Unregulated, excessive ADH.

    • Serum/Urine Laboratory Balance: Dilutional Hyponatremia ($\downarrow\;\text{Na}$), low serum osmolality, high concentrated urine osmolality, high urine specific gravity.

    • Clinical Features: Severe water retention, hypervolemic expansion without peripheral dependent edema, oliguria, cerebral edema, headache, confusion, seizures, muscle cramps.

    • Therapy: Fluid restriction, loop diuretics, hypertonic ($3\%$) saline for neurological emergencies, continuous daily weight tracking, serial neurological assessments.